Yutian Zhang, Xiaoou Li, Tao Wang, Lian Liu, Bi Ran, Kangzhuo Baima, Yue Liao, Fuqiang Wen, Jun Chen, Lei Chen
{"title":"Altitude-associated circulating biomarker profiles in native Tibetans with and without chronic mountain sickness","authors":"Yutian Zhang, Xiaoou Li, Tao Wang, Lian Liu, Bi Ran, Kangzhuo Baima, Yue Liao, Fuqiang Wen, Jun Chen, Lei Chen","doi":"10.1016/j.tmaid.2026.103030","DOIUrl":null,"url":null,"abstract":"<div><h3>Aim</h3><div>Native Tibetans have adapted to chronic hypoxia, yet remain susceptible to Chronic Mountain Sickness (CMS), including high-altitude polycythemia (HAPC) and high-altitude pulmonary hypertension (HAPH). CMS prevalence rises with altitude, but mechanisms remain unclear. We aim to investigate biomarker profiles in native Tibetans with and without CMS across altitudes, including extreme altitude >5,000m.</div></div><div><h3>Methods</h3><div>We enrolled 91 native Tibetans across 4 altitudes (500 m/3,680 m/4,750 m/5,373 m), categorized into healthy, HAPC and HAPH groups. Seventeen biomarkers were quantified via Luminex. Biomarker associations with altitude and disease were analyzed using linear regression with Type-III-F-tests, followed by post-hoc comparison and effect-size analysis.</div></div><div><h3>Results</h3><div>Among healthy Tibetans, multiple biomarkers exhibited non-linear altitude-dependent changes. C-X-C motif chemokine ligand 8 (CXCL8), interferon-γ (IFN-γ), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), C-X-C motif chemokine ligand 4 (CXCL4) and thrombopoietin (TPO) peaked at 4,750 m and declined at 5,373 m, whereas matrix metalloproteinase-3 (MMP-3) increased at 5,373 m. Among plateau-dwelling Tibetans (including HAPC and HAPH), no independent main disease-status effects were detected across biomarkers. However, an altitude-disease interaction was observed for angiogenin, with reduction at 5,373 m in HAPH, but not in HAPC.</div></div><div><h3>Conclusion</h3><div>Rising altitude drives distinct biomarker profiles in healthy Tibetans, with CXCL8/IFN-γ/FGF/VEGF/CXCL4/TPO exhibiting an inverted U-shaped response peaking at 4,750 m, and isolated MMP-3 elevation at 5,373 m, indicating a transition from adaptive angiogenesis to pathological tissue remodeling at extreme-high altitude. The altitude-dependent angiogenin reduction observed exclusively in HAPH at extreme altitude, indicating a dysregulated vascular reparative signaling in Tibetans with HAPH. These findings provide new insights into CMS pathogenesis across hypoxic gradient.</div></div>","PeriodicalId":23312,"journal":{"name":"Travel Medicine and Infectious Disease","volume":"74 ","pages":"Article 103030"},"PeriodicalIF":5.6000,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Travel Medicine and Infectious Disease","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1477893926000803","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/10/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0
Abstract
Aim
Native Tibetans have adapted to chronic hypoxia, yet remain susceptible to Chronic Mountain Sickness (CMS), including high-altitude polycythemia (HAPC) and high-altitude pulmonary hypertension (HAPH). CMS prevalence rises with altitude, but mechanisms remain unclear. We aim to investigate biomarker profiles in native Tibetans with and without CMS across altitudes, including extreme altitude >5,000m.
Methods
We enrolled 91 native Tibetans across 4 altitudes (500 m/3,680 m/4,750 m/5,373 m), categorized into healthy, HAPC and HAPH groups. Seventeen biomarkers were quantified via Luminex. Biomarker associations with altitude and disease were analyzed using linear regression with Type-III-F-tests, followed by post-hoc comparison and effect-size analysis.
Results
Among healthy Tibetans, multiple biomarkers exhibited non-linear altitude-dependent changes. C-X-C motif chemokine ligand 8 (CXCL8), interferon-γ (IFN-γ), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF), C-X-C motif chemokine ligand 4 (CXCL4) and thrombopoietin (TPO) peaked at 4,750 m and declined at 5,373 m, whereas matrix metalloproteinase-3 (MMP-3) increased at 5,373 m. Among plateau-dwelling Tibetans (including HAPC and HAPH), no independent main disease-status effects were detected across biomarkers. However, an altitude-disease interaction was observed for angiogenin, with reduction at 5,373 m in HAPH, but not in HAPC.
Conclusion
Rising altitude drives distinct biomarker profiles in healthy Tibetans, with CXCL8/IFN-γ/FGF/VEGF/CXCL4/TPO exhibiting an inverted U-shaped response peaking at 4,750 m, and isolated MMP-3 elevation at 5,373 m, indicating a transition from adaptive angiogenesis to pathological tissue remodeling at extreme-high altitude. The altitude-dependent angiogenin reduction observed exclusively in HAPH at extreme altitude, indicating a dysregulated vascular reparative signaling in Tibetans with HAPH. These findings provide new insights into CMS pathogenesis across hypoxic gradient.
期刊介绍:
Travel Medicine and Infectious Disease
Publication Scope:
Publishes original papers, reviews, and consensus papers
Primary theme: infectious disease in the context of travel medicine
Focus Areas:
Epidemiology and surveillance of travel-related illness
Prevention and treatment of travel-associated infections
Malaria prevention and treatment
Travellers' diarrhoea
Infections associated with mass gatherings
Migration-related infections
Vaccines and vaccine-preventable disease
Global policy/regulations for disease prevention and control
Practical clinical issues for travel and tropical medicine practitioners
Coverage:
Addresses areas of controversy and debate in travel medicine
Aims to inform guidelines and policy pertinent to travel medicine and the prevention of infectious disease
Publication Features:
Offers a fast peer-review process
Provides early online publication of accepted manuscripts
Aims to publish cutting-edge papers